126 related articles for article (PubMed ID: 11479206)
1. Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients.
Taback B; Fujiwara Y; Wang HJ; Foshag LJ; Morton DL; Hoon DS
Cancer Res; 2001 Aug; 61(15):5723-6. PubMed ID: 11479206
[TBL] [Abstract][Full Text] [Related]
2. Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients.
Fujiwara Y; Chi DD; Wang H; Keleman P; Morton DL; Turner R; Hoon DS
Cancer Res; 1999 Apr; 59(7):1567-71. PubMed ID: 10197630
[TBL] [Abstract][Full Text] [Related]
3. Detection of tumor-specific genetic alterations in bone marrow from early-stage breast cancer patients.
Taback B; Giuliano AE; Hansen NM; Singer FR; Shu S; Hoon DS
Cancer Res; 2003 Apr; 63(8):1884-7. PubMed ID: 12702578
[TBL] [Abstract][Full Text] [Related]
4. Meningiomas: loss of heterozygosity on chromosome 10 and marker-specific correlations with grade, recurrence, and survival.
Mihaila D; Jankowski M; Gutiérrez JA; Rosenblum ML; Newsham IF; Bögler O; Rempel SA;
Clin Cancer Res; 2003 Oct; 9(12):4443-51. PubMed ID: 14555517
[TBL] [Abstract][Full Text] [Related]
5. Detection and characterization of circulating microsatellite-DNA in blood of patients with breast cancer.
Schwarzenbach H; Müller V; Stahmann N; Pantel K
Ann N Y Acad Sci; 2004 Jun; 1022():25-32. PubMed ID: 15251935
[TBL] [Abstract][Full Text] [Related]
6. Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression.
Schwarzenbach H; Eichelser C; Kropidlowski J; Janni W; Rack B; Pantel K
Clin Cancer Res; 2012 Oct; 18(20):5719-30. PubMed ID: 23014523
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of preoperative molecular serum analysis in renal cancer.
Gonzalgo ML; Eisenberger CF; Lee SM; Trock BJ; Marshall FF; Hortopan S; Sidransky D; Schoenberg MP
Clin Cancer Res; 2002 Jun; 8(6):1878-81. PubMed ID: 12060631
[TBL] [Abstract][Full Text] [Related]
8. Loss of heterozygosity at D8S298 is a predictor for long-term survival of patients with tumor-node-metastasis stage I of hepatocellular carcinoma.
Pang JZ; Qin LX; Ren N; Hei ZY; Ye QH; Jia WD; Sun BS; Lin GL; Liu DY; Liu YK; Tang ZY
Clin Cancer Res; 2007 Dec; 13(24):7363-9. PubMed ID: 18094418
[TBL] [Abstract][Full Text] [Related]
9. Microsatellite DNA alterations of gastrointestinal stromal tumors are predictive for outcome.
Schurr P; Wolter S; Kaifi J; Reichelt U; Kleinhans H; Wachowiak R; Yekebas E; Strate T; Kalinin V; Simon R; Sauter G; Schaefer H; Izbicki J
Clin Cancer Res; 2006 Sep; 12(17):5151-7. PubMed ID: 16951233
[TBL] [Abstract][Full Text] [Related]
10. Allelic loss at 16q23.2 is associated with good prognosis in high grade prostate cancer.
Fromont G; Valeri A; Cher M; Pontes JE; Vallancien G; Validire P; Latil A; Cussenot O
Prostate; 2005 Dec; 65(4):341-6. PubMed ID: 16015610
[TBL] [Abstract][Full Text] [Related]
11. Association between recurrence of sporadic colorectal cancer, high level of microsatellite instability, and loss of heterozygosity at chromosome 18q.
Sarli L; Bottarelli L; Bader G; Iusco D; Pizzi S; Costi R; D'Adda T; Bertolani M; Roncoroni L; Bordi C
Dis Colon Rectum; 2004 Sep; 47(9):1467-82. PubMed ID: 15486743
[TBL] [Abstract][Full Text] [Related]
12. Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer.
Schwarzenbach H; Chun FK; Müller I; Seidel C; Urban K; Erbersdobler A; Huland H; Pantel K; Friedrich MG
BJU Int; 2008 Jul; 102(2):253-8. PubMed ID: 18336598
[TBL] [Abstract][Full Text] [Related]
13. Allelic loss is heterogeneous throughout the tumor in colorectal carcinoma.
Lindforss U; Fredholm H; Papadogiannakis N; Gad A; Zetterquist H; Olivecrona H
Cancer; 2000 Jun; 88(12):2661-7. PubMed ID: 10870047
[TBL] [Abstract][Full Text] [Related]
14. [Detailed mapping and clinical significance of loss of heterozygosity on 9p13-23 in laryngeal squamous cell carcinoma by microsatellite analysis].
Xu XF; Tang PZ; Cheng SJ
Ai Zheng; 2003 May; 22(5):452-7. PubMed ID: 12753701
[TBL] [Abstract][Full Text] [Related]
15. Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: from the Danish "MALOVA" Ovarian Carcinoma Study.
Høgdall EV; Ryan A; Kjaer SK; Blaakaer J; Christensen L; Bock JE; Glud E; Jacobs IJ; Høgdall CK
Cancer; 2004 Jun; 100(11):2387-95. PubMed ID: 15160342
[TBL] [Abstract][Full Text] [Related]
16. Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival.
Silva JM; Silva J; Sanchez A; Garcia JM; Dominguez G; Provencio M; Sanfrutos L; Jareño E; Colas A; España P; Bonilla F
Clin Cancer Res; 2002 Dec; 8(12):3761-6. PubMed ID: 12473587
[TBL] [Abstract][Full Text] [Related]
17. Microsatellite analysis of serum DNA in patients with oral squamous cell carcinoma.
Kakimoto Y; Yamamoto N; Shibahara T
Oncol Rep; 2008 Nov; 20(5):1195-200. PubMed ID: 18949421
[TBL] [Abstract][Full Text] [Related]
18. [Minimal commonly deleted regions on chromosome 7q31 in primary gastric carcinoma and its clinical significance].
Li JT; Fu L; Xia JC; Feng BJ; Mai SJ; Yu XJ; Huang LX; Feng QS; Pan ZZ; Zhan YQ
Ai Zheng; 2005 Nov; 24(11):1306-11. PubMed ID: 16552953
[TBL] [Abstract][Full Text] [Related]
19. Comparison of genetic alterations detected in circulating microsatellite DNA in blood plasma samples of patients with prostate cancer and benign prostatic hyperplasia.
Müller I; Urban K; Pantel K; Schwarzenbach H
Ann N Y Acad Sci; 2006 Sep; 1075():222-9. PubMed ID: 17108215
[TBL] [Abstract][Full Text] [Related]
20. Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer.
Chen X; Bonnefoi H; Diebold-Berger S; Lyautey J; Lederrey C; Faltin-Traub E; Stroun M; Anker P
Clin Cancer Res; 1999 Sep; 5(9):2297-303. PubMed ID: 10499596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
